Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07312578) titled 'Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
Drug: Nimotuzumab
Drug: camrelizumab
Drug: Albumin paclitaxel
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: November 1, 2025
Target Sample Size: 48
Countries of Recruitment:
China
To know mor...